Aachen

• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo … Ended recruitment
  2023-506526-37-00 5 2021-03-17 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended recruitment
  2024-513433-20-00 4 2020-12-16 Limited Disease Small Cell Lung Cancer
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co … Ended recruitment
  2024-518033-28-00 6 2020-11-27 Prophylaxis of transplant rejection in adult liver allograft recipient
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t … Ended recruitment
  2024-516271-32-00 5 2020-06-03 Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok … Ended recruitment
  2023-505810-12-00 5 2019-09-03 Lower limb spasticity
• Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended recruitment
  2024-515375-35-00 4 2019-08-26 Untreated patients with higher risk MDS and oligoblastic AML eligible
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Ended recruitment
  2024-515769-32-00 5 2019-07-02 HR+/HER2- early breast cancer
• A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended recruitment
  2024-512585-34-00 4 2019-02-27 Indolent Systemic Mastocytosis (ISM)
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat … Ended recruitment
  2024-513912-89-00 10 2018-12-13 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended recruitment
  2024-512212-21-00 5 2017-11-28 Advanced hepatocellular carcinoma (HCC)

Showing 193–216 of 279 trials